Replimune Wins 10-3 FDA Panel Vote for Melanoma Drug RP1

The FDA's own scientists wrote that Replimune's melanoma data didn't prove the drug works. Its advisory panel read the same pages and voted decisively in favor anyway.

The other panel today delivered a lopsided rejection of Capricor's Duchenne cell therapy. Johnson and Johnson put two point five eight billion behind in vivo CAR-T. Alnylam lost twenty-nine percent before lunch. Busy Thursday. Let's get into it.

Welcome to The Pharma Closeout for Thursday, July 30th. I'm Alex Mercer.

And I'm Maya Patel.

Ten to three. That's the vote, and the language in the question matters — panelists concluded the efficacy results from Replimune's key study were evaluable and clinically meaningful. The decision is coming up in just a few days.

We told you Wednesday we'd be back in those briefing documents, because that's where this looked decided. What the reviewers actually wrote: the study didn't conclusively prove the drug helps patients, and the survival analysis wasn't interpretable. The stock dropped forty percent on that. A day later, the panel read the identical pages and went the other way.

And this isn't a first attempt. This marks another attempt, after RP1 has already been turned back multiple times. The agency accepted the resubmission and set a decision date in the near term, and slotted the panel in between. A no on Monday means Replimune waits on the confirmatory trial — late 2027 — before it can file anything again.

The evidence problem is architectural. Single-arm, no control. RP1 goes into the tumor. It's given on top of Opdivo, which is systemic. About a third of patients had some tumor response, fifteen percent complete remission. The agency's objection was that you can't separate what the injection did from what the checkpoint inhibitor did.

My read is this is the clearest signal yet on how flexible this FDA is willing to be. Written reviewer objections, and a panel overrode them in public.

I'd push on that. The panel didn't vote that the drug works. It voted the data were evaluable — a narrower question that leaves attribution completely untouched. And look at the survival argument the company leaned on. Responders versus non-responders. You have to live long enough to get classified a responder. That comparison favors responders by construction. It isn't evidence. It's arithmetic.

That's a fair correction. I'll take it. So the read isn't that the panel disagreed with the science — it's that the panel disagreed about how long these patients should wait for it. An MD Anderson melanoma specialist said outright the therapy should be available in the short term until the Phase 3 reads out.

Which is exactly why Monday is genuinely open. The vote is non-binding, and the agency wrote the science objection itself. There's a version where RP1 gets approved with the confirmatory trial welded into the label, and a version where the division holds, and Replimune loses significant time.

The competitive read: post-checkpoint melanoma has been a dead zone — poor response rates, thin options. If an approval lands here, on a single-arm response endpoint, over the written objection of the review division, it moves what every intratumoral and combination asset behind it can credibly walk into a filing meeting with.

And it moves what medical affairs defends for the next five years. A label built on a contested response analysis means every payer conversation and every guideline discussion re-opens the attribution question the panel just declined to answer.

Shifting to the deal side — and this one's a structure story. Johnson and Johnson announced late Wednesday it's paying seven hundred eighty-five million dollars up front to work with Sail Biomedicines. Four hundred sixty-five million of that is equity. And it holds an exclusive option to buy the company outright for two point five eight billion. Sail is a Flagship Pioneering company, built from the merger of Senda Biosciences and Laronde. Lead program is SAIL-0839. Preclinical. Target disease undisclosed.

Undisclosed target, preclinical asset, nine-figure equity check. Somebody has conviction.

Let's bring in Marcus Webb on the structure.

And the biology is where I'd slow down. Four preclinical programs, no indication disclosed on the lead, and the whole case rests on autoimmune disease — where skipping conditioning chemotherapy and the manufacturing burden is a genuinely good argument. It is also completely unproven in humans. This is a platform priced off asset one, and the second-asset test hasn't been scheduled yet.

Staying with deals, an update on Lilly and AtaiBeckley. New today in an SEC filing: AtaiBeckley drew co-development and royalty offers from other parties before it signed the two point eight billion dollar deal with Lilly. The assets are BPL-003 and VLS-01, both in treatment-resistant depression.

Competing paper on a psychedelics asset is the datapoint, not the price. Somebody else built a model that supported paying for it.

One more on the pipeline. Pfizer put out topline data from a pair of Phase 3 trials of Litfulo in nonsegmental vitiligo — TRANQUILLO and TRANQUILLO 2. Both met co-primary endpoints, significant improvements in facial and total body repigmentation versus placebo at week fifty-two, at both the fifty and one hundred milligram doses. Global filings intended.

Week fifty-two is the number I'd circle, not the effect size. Repigmentation is slow, and reading your endpoint at a full year tells you precisely what the adherence and reimbursement conversation looks like before a single script gets written. Pfizer says that if approved this would be the first oral systemic option designed to restore and maintain pigmentation in adults — and that's the read-through to Incyte. A topical franchise has never had to answer an oral competitor in extensive body-surface disease.

On the regulatory side — the other panel today, and it went the opposite way. We were tracking the Capricor meeting yesterday. What's new is the tally, and the question. The FDA's cell and gene therapy committee voted overwhelmingly against it, with no abstentions, that available evidence does not support the effectiveness of deramiocel for cardiomyopathy in Duchenne. Shares down about fifty-one and a half percent.

Non-binding, with a decision date coming up soon.

Here's the part worth catching. Per the company, the voting question addressed a narrower indication than Capricor proposed, and the committee wasn't asked to vote on overall benefit-risk at all. Separately, on upper limb function, the panel's feedback was directionally supportive of the HOPE-3 evidence — including the primary endpoint, PUL 2.0. So the pivotal endpoint was skeletal, and the vote was cardiac. That's not the data being rejected. That's the evidence architecture answering a question nobody asked it.

Two panels, one day, opposite directions.

Which is the actual signal for anyone modeling this agency. It isn't getting more permissive or less. It's getting more specific about what question the data was built to answer.

Also worth noting on the regulatory front — the FTC action against Hims and Hers we flagged yesterday. The complaint's now filed, federal court in California, with Utah and California joining.

And the allegations are specific. Sharing sensitive health information, including medical conditions, with ad platforms including Meta and Snap, despite privacy promises. Enrolling consumers into recurring prescription subscriptions before the medical consultation they were promised. Making cancellation deliberately hard. The company calls the claims baseless.

That's the direct-to-consumer channel every pharma commercial team has spent three years building toward.

Which is why the theory matters more than the defendant here. If condition-level data flowing to ad platforms is the violation, every brand sitting downstream of a telehealth funnel just inherited that exposure in its own vendor review.

Looking ahead — Alnylam, which we flagged yesterday, and the number is now on the board. Down twenty-nine percent Thursday morning. Amvuttra crossed a billion for the first time at one point zero one billion — and still missed consensus by four percent. U.S. eight hundred nine million, two percent light. Full-year ATTR guidance cut to four point two to four point five billion. Two hundred million off both ends.

The competitive context is what makes that sting. Wainua failed in CARDIO-TTRansform, and Pfizer pushed the tafamidis generic challenge to 2031. The field cleared, and the number still missed. Management points to normalized second-line growth after last year's pent-up demand, and says first-line is the focus. So the question isn't who takes share anymore. It's how fast diagnosis expands the pool.

Then the calendar. August 2nd, Replimune. August 22nd, Capricor. Both of them tests of whether panel sentiment survives contact with the review division.

If those two land in opposite directions, we'll know more about how this FDA weighs unmet need against evidence quality than we've learned in the last six months.

And that is your Pharma Closeout for Thursday, July 30th — Replimune ten to three, Capricor three to nine, J and J's two point five eight billion dollar option on Sail, Pfizer's vitiligo readout, and Alnylam handing back twenty-nine percent before noon. Two panels, one day, opposite verdicts. That's the most informative kind of day this industry produces. Follow wherever you listen and tomorrow's briefing lands on its own.

Three days between a vote and a decision letter is almost no room to move. I'll be reading the August 2nd notice for one thing — whether the confirmatory trial gets written into the label. That's the tell on how much of the panel's argument the agency actually bought.